SOL-804 is a metastatic castration-resistant prostate cancer (mCRPC) treatment developed by Dyna Therapeutics, a subsidiary of Bukwang Pharmaceutical, specializing in formulation development.
 

Dyna Therapeutics acquired the worldwide development and distribution rights of SOL-804 from Solural Pharma, a Denmark-based pharmaceutical company.
 

Existing prostate cancer treatments, which mainly contain Abiraterone acetate, have the disadvantage of being taken at least 2 hours after meals and prohibiting food consumption for at least 1 hour after taking them. Accordingly, SOL-804 is Incrementally Modified Drug(IMD) that is being developed with the aim of minimizing not only food effects but also low-dose administration by applying the drug delivery platform technology, Lymphatic Targeting Technology™.
 

In 2022, the result of phase 1 indicated that low dose of SOL-804 exerted a significant pharmacokinetic profile compared to the existing drug, Zytiga. Bukwang Pharmaceutical plans to file an IND of clinical study for approval within 2022.
 

The patent of composition of matter is registered successfully in United States and 31 countries such as Korea, Japan, Eurasia (2 countries), Europe (20 countries), Australia, Mexico, Singapore, South Africa, India, Canada, and Israel.